Drugs / E/C/F/TDF
E/C/F/TDF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01363011 | May 2011 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-05-28 | Gilead Sciences | Regulatory European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗
F/TAF is Gilead’s second F/TAF-based regimen to be validated by the EMA. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-05-28 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E/C/F/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01363011 ↗ |
| Known as | elvitegravir/cobicistat/emtricitabine/tenofovir DF | “elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n = 33) achieved high rates of virologic success” PMID 25469527 ↗ Mar 2015 |
| Known as | STB | “elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n = 33) achieved high rates of virologic success” PMID 25469527 ↗ Mar 2015 |
| Route | Oral | “administered orally once daily” NCT01363011 ↗ |